PE20071115A1 - Compuestos dimeros agonistas de los receptores fgf (fgfr) y su proceso de preparacion - Google Patents
Compuestos dimeros agonistas de los receptores fgf (fgfr) y su proceso de preparacionInfo
- Publication number
- PE20071115A1 PE20071115A1 PE2007000034A PE2007000034A PE20071115A1 PE 20071115 A1 PE20071115 A1 PE 20071115A1 PE 2007000034 A PE2007000034 A PE 2007000034A PE 2007000034 A PE2007000034 A PE 2007000034A PE 20071115 A1 PE20071115 A1 PE 20071115A1
- Authority
- PE
- Peru
- Prior art keywords
- methylindolizin
- carbonyl
- bis
- alkyl
- aminobenzoic acid
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
REFERIDA A UN COMPUESTO HETEROCICLICO DE FORMULA GENERAL M1-L-M2, DONDE L ES UN GRUPO DE UNION TAL COMO UN RADICAL ALQUILENO, ALQUENILO O ALQUINILO, LINEAL O RAMIFICADO, DE 2 A 25 ATOMOS DE CARBONO, ENTRE OTROS, QUE UNE M1 Y M2 DE MANERA COVALENTE Y M1 O M2 SON IDENTICOS O DIFERENTES Y REPRESENTAN UNA UNIDAD MONOMERA DE FORMULA (M), DONDE X ES N O CR2*; A ES CO O SO2; EL SIMBOLO ASTERISCO INDICA EL SITIO DE UNION ENTRE L Y M1Y ENTRE L Y M2, ESTANDO SITUADO DICHO SITIO DE UNION EN UNO DE LOS SUSTITUYENTES R, R1 O R2; R ES H, HALOGENO, ALQUILO C1-C5, OH, ENTRE OTROS; R1 ES H, HALOGENO, CO2R5, ENTRE OTROS; R5 ES H, ALQUILO C1-C5, BENCILO; R2 ES ALQUILO C1-C5, CICLOALQUILO C3-C6, FENILO, ENTRE OTROS; R3 Y R4 SON H, OH, AMINO, NITRO, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: SAL DISODICA DE 3,3'-{3,6,9,12,15-PENTA OXAHEPTADECANO-1,17-DIILBIS[OXI(1-METOXI-2-METILINDOLIZIN-8,3-DIIL)CARBONIL]}BIS(ACIDO 6-AMINOBENZOICO), SAL DISODICA DE 3,3'-{3,6,9,12,15,18-HEXAOXAICOSANO-1,20-DIILBIS[OXI(1-METOXI-2-METILINDOLIZIN-6,3-DIIL)CARBONIL]}BIS(ACIDO 6-AMINOBENZOICO), SAL DISODICA DE 3,3'-{ETANO-1,2-DIILBIS[OXIETANO-2,1-DIILOXI-3,1-FENILENMETILENOXI(2-METILINDOLIZIN-1,3-DIIL)CARBONIL]}BIS(ACIDO 6-AMINOBENZOICO), ENTRE OTROS. TAMBIEN ESTA REFERIDO A UNA COMPOSICION Y A UN PROCEDIMIENTO DE PREPARACION. DICHOS COMPUESTOS SON AGONISTAS DE LOS RECEPTORES DE LOS FACTORES DE CRECIMIENTO DE LOS FIBROBLASTOS (FGFR) Y SON UTILES EN EL TRATAMIENTO DE PATOLOGIAS RELACIONADAS CON LA ANGIOGENESIS
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0600317A FR2896247B1 (fr) | 2006-01-13 | 2006-01-13 | Composes dimeres agonistes des recepteurs des fgfs (fgfrs), leur procede de preparation et leur application en therapeutique |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20071115A1 true PE20071115A1 (es) | 2007-12-14 |
Family
ID=36808846
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2007000034A PE20071115A1 (es) | 2006-01-13 | 2007-01-12 | Compuestos dimeros agonistas de los receptores fgf (fgfr) y su proceso de preparacion |
Country Status (37)
| Country | Link |
|---|---|
| US (1) | US9120819B2 (es) |
| EP (1) | EP2018165B1 (es) |
| JP (1) | JP5286088B2 (es) |
| KR (1) | KR101378220B1 (es) |
| CN (1) | CN101384258B (es) |
| AR (1) | AR059001A1 (es) |
| AT (1) | ATE505188T1 (es) |
| AU (1) | AU2007204252B2 (es) |
| BR (1) | BRPI0707132A2 (es) |
| CA (1) | CA2633057C (es) |
| CR (1) | CR10097A (es) |
| CY (1) | CY1111688T1 (es) |
| DE (1) | DE602007013889D1 (es) |
| DK (1) | DK2018165T3 (es) |
| EA (1) | EA015046B1 (es) |
| EC (1) | ECSP088592A (es) |
| ES (1) | ES2364857T3 (es) |
| FR (1) | FR2896247B1 (es) |
| HK (1) | HK1130009A1 (es) |
| HN (1) | HN2008001067A (es) |
| HR (1) | HRP20110514T1 (es) |
| IL (1) | IL192403A (es) |
| JO (1) | JO2659B1 (es) |
| MA (1) | MA30214B1 (es) |
| MX (1) | MX2008009010A (es) |
| NO (1) | NO20083406L (es) |
| NZ (1) | NZ569631A (es) |
| PE (1) | PE20071115A1 (es) |
| PL (1) | PL2018165T3 (es) |
| PT (1) | PT2018165E (es) |
| RS (1) | RS51872B (es) |
| SI (1) | SI2018165T1 (es) |
| TN (1) | TNSN08250A1 (es) |
| TW (1) | TWI386408B (es) |
| UA (1) | UA95469C2 (es) |
| WO (1) | WO2007080325A1 (es) |
| ZA (1) | ZA200806547B (es) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2883286B1 (fr) * | 2005-03-16 | 2008-10-03 | Sanofi Aventis Sa | NOUVEAUX DERIVES D'IMIDAZO[1,5-a]PYRIDINES, INHIBITEURS DE FGFs, LEUR PROCEDE DE PREPARATION ET LES COMPOSITIONS PHARMACEUTIQUES LES CONTENANT |
| EP2270043A1 (en) | 2009-07-03 | 2011-01-05 | Sanofi-Aventis | Extracellular allosteric inhibitor binding domain from a tyrosine kinase receptor |
| US9226960B2 (en) | 2010-04-16 | 2016-01-05 | Andrew B. Bush | FGF modulation of in vivo antibody production and humoral immunity |
| FR2962437B1 (fr) * | 2010-07-06 | 2012-08-17 | Sanofi Aventis | Derives d'imidazopyridine, leur procede de preparation et leur application en therapeutique |
| FR2962438B1 (fr) | 2010-07-06 | 2012-08-17 | Sanofi Aventis | Derives d'indolizines, procedes de preparation et application en therapeutique |
| US8901341B2 (en) | 2011-02-11 | 2014-12-02 | Bezwada Biomedical, Llc | Amino acid derivatives and absorbable polymers therefrom |
| WO2012167261A2 (en) | 2011-06-03 | 2012-12-06 | Yale University | Compositions and methods for treating and preventing neointimal stenosis |
| FR2982261B1 (fr) * | 2011-11-04 | 2014-06-13 | Galderma Res & Dev | Nouveaux amides, et leur utilisation pharmaceutique ou cosmetique |
| FR2985258A1 (fr) * | 2011-12-28 | 2013-07-05 | Sanofi Sa | Composes dimeres agonistes des recepteurs des fgfs (fgfrs), leur procede de preparation et leur application en therapeutique |
| FR2985257B1 (fr) * | 2011-12-28 | 2014-02-14 | Sanofi Sa | Composes dimeres agonistes des recepteurs des fgfs (fgfrs), leur procede de preparation et leur application en therapeutique |
| FR2985185B1 (fr) * | 2012-01-04 | 2013-12-27 | Sanofi Sa | Utilisation en therapeutique de derives d'imidazopyridine |
| WO2014144952A2 (en) | 2013-03-15 | 2014-09-18 | Peter Walter | Modulators of the eif2alpha pathway |
| EP2994130A4 (en) * | 2013-05-06 | 2017-02-22 | Bush, Andrew B. | Fgf modulation of in vivo antibody production and humoral immunity |
| CA3007631A1 (en) | 2015-12-11 | 2017-06-15 | Research Institute At Nationwide Children's Hospital | Optimized patient specific non-linear tissue engineered vascular grafts |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ193926A (en) | 1979-07-06 | 1984-05-31 | Labaz Sanofi Nv | 2-(alkyl or phenyl)-3(4-hydroxybenzoyl)indolizines |
| FR2838123B1 (fr) * | 2002-04-04 | 2005-06-10 | Sanofi Synthelabo | Nouveaux derives d'indolozine-1,2,3 substituee, inhibiteurs selectifs du b-fgf |
| ATE496064T1 (de) | 2002-05-07 | 2011-02-15 | Novo Nordisk As | Lösliche formulierungen, die monomeres insulin und acyliertes insulin enthalten |
| FR2859997B1 (fr) | 2003-09-18 | 2006-02-03 | Sanofi Synthelabo | Nouveaux derives d'indolizine 1,2,3,6,7,8 substituee, inhibiteurs des fgfs, leur procede de preparation et les compositions pharmaceutiques les contenant. |
-
2006
- 2006-01-13 FR FR0600317A patent/FR2896247B1/fr not_active Expired - Fee Related
-
2007
- 2007-01-11 JO JO20078A patent/JO2659B1/en active
- 2007-01-12 BR BRPI0707132-9A patent/BRPI0707132A2/pt not_active IP Right Cessation
- 2007-01-12 ZA ZA200806547A patent/ZA200806547B/xx unknown
- 2007-01-12 KR KR1020087019763A patent/KR101378220B1/ko not_active IP Right Cessation
- 2007-01-12 NZ NZ569631A patent/NZ569631A/en not_active IP Right Cessation
- 2007-01-12 AT AT07717861T patent/ATE505188T1/de active
- 2007-01-12 PL PL07717861T patent/PL2018165T3/pl unknown
- 2007-01-12 CA CA2633057A patent/CA2633057C/fr not_active Expired - Fee Related
- 2007-01-12 ES ES07717861T patent/ES2364857T3/es active Active
- 2007-01-12 TW TW096101264A patent/TWI386408B/zh not_active IP Right Cessation
- 2007-01-12 PE PE2007000034A patent/PE20071115A1/es not_active Application Discontinuation
- 2007-01-12 EA EA200870167A patent/EA015046B1/ru not_active IP Right Cessation
- 2007-01-12 DK DK07717861.4T patent/DK2018165T3/da active
- 2007-01-12 JP JP2008549908A patent/JP5286088B2/ja not_active Expired - Fee Related
- 2007-01-12 SI SI200730643T patent/SI2018165T1/sl unknown
- 2007-01-12 RS RS20110305A patent/RS51872B/en unknown
- 2007-01-12 WO PCT/FR2007/000051 patent/WO2007080325A1/fr active Application Filing
- 2007-01-12 PT PT07717861T patent/PT2018165E/pt unknown
- 2007-01-12 AR ARP070100146A patent/AR059001A1/es not_active Application Discontinuation
- 2007-01-12 EP EP07717861A patent/EP2018165B1/fr active Active
- 2007-01-12 CN CN2007800052555A patent/CN101384258B/zh not_active Expired - Fee Related
- 2007-01-12 AU AU2007204252A patent/AU2007204252B2/en not_active Ceased
- 2007-01-12 DE DE602007013889T patent/DE602007013889D1/de active Active
- 2007-01-12 MX MX2008009010A patent/MX2008009010A/es active IP Right Grant
- 2007-12-01 UA UAA200810356A patent/UA95469C2/ru unknown
-
2008
- 2008-06-10 TN TNP2008000250A patent/TNSN08250A1/en unknown
- 2008-06-20 CR CR10097A patent/CR10097A/es not_active IP Right Cessation
- 2008-06-23 IL IL192403A patent/IL192403A/en not_active IP Right Cessation
- 2008-07-01 EC EC2008008592A patent/ECSP088592A/es unknown
- 2008-07-10 HN HN2008001067A patent/HN2008001067A/es unknown
- 2008-07-11 US US12/171,373 patent/US9120819B2/en not_active Expired - Fee Related
- 2008-08-04 NO NO20083406A patent/NO20083406L/no not_active Application Discontinuation
- 2008-08-08 MA MA31166A patent/MA30214B1/fr unknown
-
2009
- 2009-09-02 HK HK09108015.5A patent/HK1130009A1/xx not_active IP Right Cessation
-
2011
- 2011-07-11 HR HR20110514T patent/HRP20110514T1/hr unknown
- 2011-07-13 CY CY20111100683T patent/CY1111688T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20071115A1 (es) | Compuestos dimeros agonistas de los receptores fgf (fgfr) y su proceso de preparacion | |
| ES2568009T3 (es) | Procedimiento para la absorción de CO2 a partir de una mezcla gaseosa con un medio de absorción que contiene aminas | |
| CO5670352A2 (es) | Piperidinas anilinicas sustituidas como antagonistas selectivos de la hormona de concentracion de melanina | |
| PE20071286A1 (es) | Composicion para inducir tolerancia viral en plantas | |
| ES2570756T3 (es) | Derivados pirimidinilpirrolopiridinona sustituidos, proceso para su preparación y su uso como inhibidores de cinasa | |
| AR106942A2 (es) | Compuestos de isoindolina y composiciones farmacéuticas de los mismos | |
| PE20081174A1 (es) | Inhibidores de metaloproteasas derivados de heterociclos | |
| CO5611131A2 (es) | Derivados de 5-feniltiazol y su uso como inhibidores de pi3 cinasa | |
| PE20060620A1 (es) | Analogos de biaril piperazinil-piridina sustituidos como moduladores del receptor de capsaicina vr1 | |
| CO6241076A2 (es) | Compuestos de benzamida y aplicaciones de los mismos | |
| AR061858A1 (es) | Compuestos heterociclicos de fosfonatos y fosfinatos, composiciones farmaceuticas que los contienen y usos como agentes antidiabeticos. | |
| CO6210811A2 (es) | Inhibidores de aldh-2 en el tratamiento de la adiccion | |
| AR069596A1 (es) | Regulador del crecimiento de plantas | |
| PE20071285A1 (es) | Composicion para inducir la tolerancia de plantas contra bacteriosis | |
| NI200900037A (es) | Derivados de 2-aril-6-fenil-imidazo[1,2-alfa] piridinas, su preparación y su aplicación en terapéutica. | |
| PE20071254A1 (es) | Derivados de sulfonamidas como agentes moduladores de los receptores de orexina y su preparacion | |
| AR072508A1 (es) | Inhibidores alfa 7 nicotinicos del receptor de acetilcolina | |
| AR054130A1 (es) | Procedimiento para la preparacion de 1-alquil-3-feniluracilos | |
| CO6140053A2 (es) | Proceso para fabricar 2-amino-5-halobenzamidas 3-sustituidas | |
| UY29346A1 (es) | 2-fenil-indoles como antagonistas del receptor de la prostaglandina d2 | |
| PE20061335A1 (es) | Compuestos derivados de benzodioxano y benzodioxolano como moduladores del receptor 5-ht2c | |
| MY139988A (en) | Macrocylic inhibitors of hepatitis c virus | |
| AR032466A1 (es) | Ciclilamina sulfonamidas, utilizacion de las mismas para la manufactura de un medicamento y composiciones farmaceuticas utiles como agonistas de los receptores beta-3 adrenergicos | |
| AR053340A1 (es) | Derivados de trifluormetilbenzamida y sus usos terapeuticos | |
| PE20130191A1 (es) | Combinaciones que contienen 2, 3-dihidroimidazo[1, 2-c]quinazolina sustituida |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration | ||
| FD | Application declared void or lapsed |